Validating scales of fatigue in multiple sclerosis
Brief summary Researchers from the Australian National University (ANU), in Canberra, Australia, are seeking volunteers with multiple sclerosis (MS) to complete an online survey about their experiences of fatigue as part of a study to develop a measure of fatigue for people living with MS. The survey is confidential and should take between 15 and […]
Collecting better data on sleep in people living with MS
Brief summary Measuring sleep well is not straightforward. In this study, we would like to work out how to best measure sleep in people with MS, and we would like to seek your feedback on the acceptability of different ways of measuring sleep. The different ways of measuring include using an activity monitor (a research […]
Asymmetry of Muscle Activation in Multiple Sclerosis
Brief summary Our research uses advanced neuroscience techniques to explore how the nervous system controls muscles in multiple sclerosis, with a particular focus on muscle weakness, fatigue and sensorimotor function. Ultimately, we aim to identify how specific neurophysiological changes due to MS influence movement and disability (e.g. mobility impairment) so that future treatments can be […]
A co-design study to develop a tailored internet psychological intervention for depression among individuals with MS
The aim of this project is to use a co-design study to inform the development of an internet-based intervention for depression targeting individuals with multiple sclerosis (MS). We will run co-design/focus groups or individual interviews with individuals with MS, health professionals who treat individuals with MS and carers of those with MS. We aim to […]
The Multiple Sclerosis Australian Women’s Midlife Years (MS-AMY) Study
Researchers at Monash University are undertaking a study to understand the physical health and psychological, sexual and socioeconomic wellbeing of Australian midlife women living with MS. The team wants to assess the contribution of common midlife circumstances, including the impact of menopause, on the quality of life of women living with MS. Surprisingly very little […]
Clinical trial of lifestyle interventions for weight management in adults living with MS
Obesity can increase the risk of developing MS and may increase levels of disability in those with established MS. Losing weight can help improve more than just body size, but it can be difficult to do and needs the support of a healthcare team to aid behaviour change. This study will use a tested method […]
STRONG-MS: Bone health and muscle health in MS
This study is a randomised controlled trial evaluating ONERO™. This is a High-intensity Resistance and Impact Training (HiRIT) exercise intervention that has potential benefits for bone health and muscle strength in people with (MS). Qualified physiotherapists will supervise balance exercises, impact movements and weightlifting in twice-weekly, 30-minute sessions. Participation involves a total of 24 months. […]
Fatigue In Relapsing Multiple Sclerosis – Epstein Barr Virus (FIRMS-EBV) Treatment Trial
Fatigue is a common symptom for many people with MS and it does not respond to traditional MS treatments. It has been suggested that fatigue in MS could relate to chronic infection with the Epstein Barr Virus (EBV). In this clinical trial, two drug therapies with antiviral effects against EBV will be tested for their […]
The MS Family Study
Researchers from the Menzies Institute for Medical Research are seeking participants who come from families with multiple relatives affected by multiple sclerosis (MS). By analysing the genetic code of such families, the researchers want to better understand the inherited risk of MS.
Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial
To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]